

# Advances in the Pharmacogenomics of Adverse Drug Reactions

Susannah L. Collins<sup>1</sup> · Daniel F. Carr<sup>1</sup> · Munir Pirmohamed<sup>1</sup>

Published online: 9 December 2015  
© Springer International Publishing Switzerland 2015

**Abstract** Rapid developments in pharmacogenomics have been noticeable in recent years, and much of this knowledge has improved understanding of adverse drug reactions. This improved knowledge has largely been the result of improved sequencing technologies and falling costs in this area, as well as improved statistical techniques to analyse the data derived from studies. While the genetic reasons behind adverse drug reactions are becoming better understood, translation of this knowledge, particularly in terms of biomarkers that might be clinically applicable at the bedside, has been more difficult. Understanding of the technologies and their application is limited among practising clinicians. The cost of some of the technologies available may also be prohibitive in stretched healthcare economies. As education about the potential for applying pharmacogenomics improves and costs fall, understanding of adverse drug reactions and application of this knowledge in a clinical setting should improve.

## Key Points

The increased accessibility of genomics technologies has significantly aided the advancement of our understanding of the pharmacogenetics of adverse drug reactions (ADRs). Next-generation sequencing methodologies will help to continue this advancement.

Many examples now exist of pharmacogenetic markers of ADRs. However, only a very small number have made the translation from discovery to clinical practice.


Widespread uptake of pharmacogenetic typing into healthcare practice still faces significant hurdles, including determining the nature of evidence that will be required, the availability and cost effectiveness of pre-prescription genotyping, and better education of the workforce.

✉ Munir Pirmohamed  
munirp@liv.ac.uk

<sup>1</sup> Department of Molecular and Clinical Pharmacology,  
University of Liverpool, Liverpool, UK

## 1 Introduction

Pharmacogenomics is the term used to describe the role of the human genome in drug response. Knowledge of the relevance of an individual's genetic make-up in their response to drugs was recognized as long ago as 1959, just 6 years after the structure of DNA was discovered [1], when the term 'pharmacogenetics' was first used by Vogel [2]. Even before this, the condition Favism (later shown to be due to G6PD deficiency) had been recognized since ancient Greek times. However, it is only really since the



**Fig. 1** Number of publications, in PubMed, in pharmacogenetics or pharmacogenomics over the years. For 2015 (*open square*), data to 29 September 2015 have been extrapolated pro rata to forecast the number of publications for the year

completion of the first full human genome sequence in 2001 [3] that research in this area has expanded (Fig. 1). Pharmacogenomics represents one component of the overall field of personalized medicine, an area of medicine where the ambition is to tailor procedures and therapeutics to an individual's make-up (disease sub-type, genetic, environmental, and clinical), maximizing the success and minimizing any potential adverse effects. Translating the discovery of pharmacogenetic biomarkers into interventions at the bedside has been less successful than at first hoped, with a few notable exceptions, and this review will aim to explore why this is and what could be done to improve this process [4, 5].

## 2 Variability in Drug Response

The efficacy of drugs varies widely, with only a proportion (which varies according to disease and drug) of patients responding. Adverse drug reactions (ADRs) account for between 6.5 % (hospital admissions) and 25 % (primary care) of attendances seeking medical help, and therefore are a significant burden on healthcare services [6]. ADRs cost in excess of £1 billion every year in the UK, with equivalent figures in other countries [7], so there is a clear benefit to understanding their causes (including genetic) and preventing them. Furthermore, between 1990 and 2013, 43 drugs were withdrawn from the market due to severe ADRs [8].

ADRs mimic naturally occurring disease, can affect any bodily system, can be of any severity, and, in some cases, can lead to the death of a patient. Some reactions can affect multiple systems, for example hypersensitivity reactions, which are immunologically mediated. Table 1 lists some of the ADRs by bodily system.

According to the classification proposed by Rawlins and Thompson [9], ADRs themselves can be dose dependent

and predictable (Type A), or apparently dose independent, unpredictable, and unrelated to the known pharmacology of the drug (Type B). Other classifications have also been proposed, including the DoTS (Dose, Time and Susceptibility) classification, where the adverse reaction is classified by dose relatedness, timing and individual susceptibility [6, 10].

## 3 Identifying Genomic Biomarkers

The International HapMap Project [11] was the first platform where genome-wide data on common single nucleotide polymorphisms (SNPs) across different populations, that might cause different drug responses, could be explored. This project started with the aim of determining common patterns of DNA sequence variation and then making this information freely available. The aim of the HapMap Project was to identify common sequence variants that predisposed to diseases, identifying new drug targets and markers of variability in drug response. We differ in approximately 0.1 % of our human genomes, which still equates to 3 million bases. These variants can be used for focused candidate gene, linkage-based and genome-wide association studies (GWAS) [11]. The latter is now becoming commonplace, but the vast majority of genome-wide studies have focused on complex diseases, with only a small percentage focusing on drug response [12]. A particular issue with GWAS is the need for large sample sizes when the effect size is relatively small, for example in complex diseases such as type 2 diabetes. However, with drug-response phenotypes, much smaller sample sizes have been needed to produce significant results because of larger effect sizes [13]. This is fortuitous given that large sample sizes are rarely available for pharmacogenomic phenotypes, especially for ADRs. Additionally, the large effect size has allowed the deployment of these genetic variants into clinical practice for prediction of ADRs.

While the HapMap Project provided data on common variants, the 1000 Genomes Project [14] has expanded and enriched this further by supplying data on rare genetic variants. Next-generation sequencing, explored further later, will only add to this bank of data. This is already being applied to drug-metabolizing enzyme genes; for example, sequence-based analysis of coding variants in 12 cytochrome P450 (CYP) genes that are responsible for the metabolism of 75 % of drugs [13] showed that between 7.6 and 11.7 % of individuals carry at least one potentially deleterious variant. Unfortunately, one of the recognized problems with current sequencing technologies for genotyping is that all platforms have systematic weaknesses and, as such, no gold standard for low- or high-depth sequencing exists [15].

**Table 1** Recognized adverse drug reactions by system, with exemplar causal drugs and indications

System	Reactions	Example causal drugs	Indication
Skin	Hypersensitivity:	Abacavir [94], nevirapine [95]	HIV
	Maculopapular exanthema,	Carbamazepine [96, 97], phenytoin [98]	Epilepsy
	DRESS, SJS, TEN	Allopurinol [99]	Gout
	UV sensitivity	Voriconazole [100]	Fungal infection
Gastrointestinal	Hepatotoxicity	Flucloxacillin [101]	Gram-positive bacterial infection
		Isoniazid [102]	Tuberculosis
		Methotrexate [103]	Rheumatoid arthritis
	Pancreatitis	Azathioprine [104]	Inflammatory bowel disease
	Lower GI disturbance	Tyrosine kinase inhibitors [105]	Non-small cell lung cancer
	Upper GI ulceration	NSAIDs [106]	Analgesia
Renal	Tubular dysfunction	Tenofovir [107]	HIV
		Aminoglycosides [108]	Pseudomonas bacterial infection
Ophthalmic	Crystalluria	Indinavir [109]	HIV
	Keratopathy, lens deposits	Amiodarone [110]	Anti-arrhythmic
	Retinopathy, lens deposits	Tamoxifen [111]	Breast cancer
		Thioridazine [110]	Anti-psychotic
Central nervous system	Suicidality	SSRIs (e.g. paroxetine) [112]	Depression
	Oculogyric crisis	Metoclopramide [113]	Antiemetic
	Neuronal toxicity, cognitive dysfunction	Efavirenz [114]	HIV
Musculoskeletal	Myopathy, rhabdomyolysis	Statins [115]	Hypercholesterolemia
		Colchicine [116]	Gout
Cardiovascular	QT prolongation (torsade de pointes)	Quinidine [117]	Anti-arrhythmic
		Erythromycin [118]	Macrolide antibiotic
Respiratory	Cardiomyopathy	Doxorubicin [119]	Anti-cancer
	Acute interstitial pneumonitis	Leflunomide [120]	Rheumatoid arthritis
	Pulmonary fibrosis	Bleomycin [121]	Testicular cancer
Maxillofacial	Angioedema	ACE inhibitors [74]	Hypertension
	Osteonecrosis of the jaw	Bisphosphonates [122]	Osteoporosis
Auditory	Ototoxicity	Cisplatin [123]	Anti-cancer
		Aminoglycosides [124]	Pseudomonas infection

*ACE* angiotensin-converting enzyme, *CV* cardiovascular, *DRESS* drug reaction with eosinophilia and systemic symptoms, *GI* gastrointestinal, *HIV* human immunodeficiency virus, *NSAID* non-steroidal anti-inflammatory drug, *SJS* Stevens–Johnson syndrome, *SSRI* selective serotonin reuptake inhibitor, *TEN* toxic epidermal necrolysis, *UV* ultra violet

### 3.1 Candidate Genes

Identifying candidate genes for selected disease processes by understanding the pathophysiology of that disease process, or by understanding the pharmacology of a drug, was possible even before the human genome was fully mapped [15]. The basis of a presumed variation is, for example, a known pathway of metabolism or a known action at a receptor. The gene encoding the enzyme or receptor can then be examined for polymorphisms that may produce variability in drug response. In most cases, a case–control study design has been used; for example, patients with and without ADRs have often been investigated in this way.

These studies have focused on variants with known functional effects, but it is important to note that even apparently non-functional SNPs can be useful, as they may be in linkage disequilibrium to causal variants [16].

A number of examples of polymorphic genes exist, identified using candidate gene approaches that have proven useful in clinical practice. For example, individual variability in dose requirements for warfarin has been shown to be dependent on polymorphisms in *CYP2C9* and *VKORC1*, which has now led to genotype-guided dosing strategies [17, 18]. Furthermore, thiopurine s-methyltransferase (TPMT) levels are now tested prior to the initiation of azathioprine; a relative or absolute deficiency of TPMT

leads to the accumulation of thioguanines increasing the risk of severe bone marrow suppression [19]. The most widely studied genes using candidate strategies have been the *CYP* genes, where polymorphisms (either loss of function or gain of function) have been associated with ADRs. *CYP2D6* was the first polymorphic phase I gene to be identified; it metabolizes 25 % of drugs [20], with 4.72–8.69 % of Caucasians being genotype-defined as poor metabolizers [21]. The reduced or absent enzyme activity leads to reduced clearance of the drug, with increased exposure and an increased risk of ADRs. An example is the  $\beta$ -blocker metoprolol, which can cause bradycardia in poor metabolizers [22]. Conversely, some individuals, up to 5.5 % of Northern Europeans, carry more than two copies of the *CYP2D6* gene and are classified as ultra-rapid metabolizers [20]. This can also lead to ADRs with pro-drugs such as codeine. Recent work has shown that ultra-rapid metabolizers, particularly infants and children, may be at increased risk of respiratory depression [18]. This has resulted in a change in the drug label by many regulatory agencies worldwide.

Although candidate gene strategies have led to some important findings, the overall success in clinical implementation has been low. There are many reasons for this, including that investigators often used small sample sizes and, in many cases, it has not been possible to replicate the associations in subsequent studies, and the genotyping and phenotyping strategies were poor. Another important limitation of a candidate gene approach is that it pre-supposes that we fully understand the mechanism by which a drug exerts beneficial and/or adverse effects, which is often not true, leading to incomplete assessment of the pathways involved in drug response.

### 3.2 Genome-Wide Association Studies

GWAS have been used to identify predisposing loci for differences in drug responses in an unbiased fashion, including inter-individual variability in the occurrence of ADRs. The advantage of GWAS over candidate gene studies is the ability to identify novel mechanisms that might cause variability in drug response between individuals, beyond the current known mechanisms of variability. GWAS uses linkage disequilibrium data to compare alleles at thousands of loci across a range of phenotypes. These SNPs then undergo regression analyses, based on the null hypothesis, to look for an association with a disease status or trait. This, the ‘discovery phase’ is then taken forward to the ‘replication phase’ whereby the SNPs with the most significant associations are retested in a new sample [23]. GWAS can identify specific gene loci, the effect of which can then be assessed in specific clinical trials [24]. One such example is the use of GWAS in assessing the

variation in adenosine diphosphate (ADP)-associated platelet aggregation with clopidogrel [25].

GWAS have been designed to detect common variants, although ‘chips’ are now becoming available, which can also enable the detection of rare variants. Furthermore, imputation techniques can allow the prediction of the existence of rare variants, but variants that exist at a minor allele frequency of <1 % will require next-generation sequencing [24, 26]. Imputation techniques have also been used to infer which human leukocyte antigen (HLA) alleles are responsible for adverse reactions, but it is important that this is confirmed by using conventional techniques to confirm the predisposing HLA locus [27–29].

The main issue with GWAS is the sample sizes currently available to researchers, particularly for rare ADRs or adverse reactions to drugs that are not widely used. International collaboration across research groups, such as that by the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) collaborative in statin-induced myopathy [30] or the iSAEC (international Serious Adverse Events Consortium), is the best way to improve sample sizes to produce good replicable findings that may have real clinical impact [24]. When several GWAS for the same phenotype have been undertaken by different groups, meta-analysis can be undertaken using imputed genotypic data across different platforms, exploiting the linkage disequilibrium across different SNPs. The drawback of imputing data is the weaknesses of various imputation methods and the bias these introduce into any such derived data [31–35]. However, like the advances in GWAS platforms and next-generation sequencing, statistical methods for interpreting genomic data are also advancing [31, 36].

### 3.3 Next-Generation Sequencing

Next-generation sequencing is an approach that can enable examination of the whole genome as well as targeted genes. It is a high-throughput parallel-sequencing approach that generates billions of short-sequence reads that are then aligned to a reference genome, enabling the investigator to identify and genotype sites of variation [37]. Like all of the technologies described here, the cost has fallen, and will continue to do so. This will enable individuals with rare or novel variants in a pharmacogene to be identified, where it may have been undetected previously using common variant analysis methodologies [38]. For instance, conventional screening assays identified 250 variants in 231 ADME (absorption, distribution, metabolism, and excretion)-related genes in an individual versus 17,733 variants using next-generation sequencing; 861 of these variants were thought to be functionally significant [38, 39]. One of the challenges of next-generation sequencing is the

analysis of data, which requires computing and bioinformatics infrastructure and expertise [38]. As with GWAS, although imputation can be performed, for rare variants identified by next-generation sequencing, linkage disequilibrium is weak between low-frequency alleles, and should be used with caution in association studies [40, 41].

Since most clinicians will not be experts in next-generation sequencing technologies, it is important to have readily accessible sources of reliable information they can use to interpret genetic variants in their patients. However, a problem in this area is that more than 30 information websites exist on pharmacogenetics and pharmacogenomics [38]. As the data from next-generation sequencing go ‘public’, there is a clear need to condense and compress these data into fewer open-source areas, so they are as easy as possible to find for those wishing to apply them. Of course, information needs to be kept as open and public as possible to maximize the benefit [38]. In addition, it is important to have quality control on the data that are generated and stored on these information portals, and that are used for clinical decision making—the latter is important, as lack of quality control will lead to incorrect decisions being made on therapy, to the detriment of the patient.

### 3.4 Rare Variant Analysis

Whole-genome sequencing for rare variants is clinically important, as many rare variants of common diseases and Mendelian inherited disorders are inherited as highly penetrative rare variants genetically [37]. Of 7000 known Mendelian disorders, less than half have identified genetic variants [15]. Genome-wide sequencing, target-region sequencing, exome sequencing, and rare-variant genotyping arrays can all be used in the design of rare variant studies and have been accompanied by the development of novel statistical methods [37]. An area of potential for rare variant analysis is whether it explains a larger proportion of the variation in predisposition to a disease or to a drug reaction than explained by common genetic variants [42]. This may lead to a genetic profile where the person’s predisposition is due to both common and rare variants; this hypothesis has not been tested to any great extent in pharmacogenomics and will require well-designed adequately powered studies.

### 3.5 Micro-RNAs

The assumption that large parts of our DNA are non-functional DNA is now known to be incorrect. In particular, certain micro-RNA (miRNA) molecules have been found to increase with certain ADRs such as drug-induced liver injury and skin reactions. In these situations, the miRNA species may both act as early biomarkers for the

disease process and provide important insights into the pathogenesis of these reactions [13]. Two recent examples are worth a mention.

Researchers in Japan have independently identified elevation of skin and serum miR-18a-5p [43] and serum miR-124 [44], respectively, in cases of toxic epidermal necrolysis, linking the miRNAs to keratinocyte apoptosis. The clinical implication is unclear, although the miRNA could have potential use as a biomarker, but this would need to be further investigated in clinical studies. Furthermore, investigating the regulatory mechanisms of keratinocyte apoptosis induced by the miRNA may lead to novel interventional strategies [43].

In paracetamol poisoning, an early rise in serum miR-122 is an indicator of liver injury, which may be applicable to liver damage caused by other drugs. Further work to evaluate the role of the miRNA, and other novel protein biomarkers, in comparison with conventional liver function tests is required to assess the prognostic value provided by these novel biomarkers in clinical settings [45, 46].

As well as circulating levels, the genetic variation of both miRNAs and miRNA regulatory binding sequences may provide a further source of inter-individual variability. Specific HLA-C allelotypes have been demonstrated in HIV patients to contain polymorphisms within the binding site of miR148a, which mediates HLA-C expression [47]. Thus, this represents an example of a genetic polymorphism that affects miRNA regulation of gene expression, where the gene itself has been previously associated with a serious ADR, namely nevirapine-induced Stevens–Johnson syndrome [48]. Although no functional association between miRNA levels and immune-mediated ADRs has been described so far, it is entirely plausible and requires further investigation.

Polymorphisms have recently been described in the *MIR133* gene that codes for miR133, which is constitutively co-expressed in hepatocytes with VKORC1 (the pharmacological target of warfarin). Polymorphisms in the *MIR133A2* gene have been associated with warfarin dosing [49], although this finding needs to be independently replicated.

## 4 Genetic Basis of Adverse Drug Reactions

Many ADRs have a genetic basis, but the overall contribution varies (but remains poorly defined). In general, variation in predisposition can be due to pharmacokinetic or pharmacodynamic factors, or a combination of both. An example of a pharmacokinetically-mediated ADR is with codeine where *CYP2D6* ultra-rapid metabolizers can form higher quantities of morphine, predisposing them to respiratory depression [50]. The variation in *HLA* genes predisposes to many immune-mediated ADRs (covered in a

recent review article [51]), and represents examples of pharmacodynamic variation. This is an area where significant advances have been made: *HLA-B\*57:01* genotyping is now used in most countries prior to the prescription of abacavir, an antiretroviral associated with hypersensitivity. A recent systematic review showed that the odds ratio of developing abacavir hypersensitivity in *HLA-B\*57:01* positive patients was 32, 177, or 859, depending on whether broad clinical criteria, strict clinical criteria, or patch testing, respectively, were used to categorize patients. Importantly, the effect of *HLA-B\*57:01* is seen across Whites, Blacks, and Hispanics [52]. This contrasts with the association of *HLA-B\*15:02* and carbamazepine-induced SJS/toxic epidermal necrolysis (TEN), which is only seen in some south-east Asian populations where the background prevalence of this HLA allele is high [8]. Non-HLA genomic biomarkers have also been identified as pharmacodynamic determinants of ADRs. For example, rare mutations in potassium channel genes have been implicated in torsade de pointes with some drugs [53]. More recently, new pharmacodynamic genetic variants have been identified for cisplatin-induced deafness [54] and vincristine-induced peripheral neuropathy [54].

An example of a drug in which both pharmacokinetic and pharmacodynamic variation increases the risk of ADRs is warfarin, where variability in *VKORC1* (a pharmacodynamic gene, the protein product of which is inhibited by warfarin) and *CYP2C9* (which is responsible for the metabolism of warfarin) not only determines the variation in daily dose requirement but also increases the risk of bleeding [55]. A multitude of studies have consistently shown an association between the response to warfarin (including daily dose) and polymorphisms in these two genes, making warfarin dosing-associated genetic polymorphisms one of the most highly replication phenotype-genotype associations [55]. However, two recent large randomized controlled trials undertaken in Europe (EU-PACT) [17] and in the USA (COAG) [56] came to different conclusions regarding the utility of genotype-guided dosing. While the EU-PACT trial showed a 7 % improvement in the time in therapeutic range using genotype-guided dosing, the COAG trial showed no difference between a genetic and a clinical algorithm. There are many reasons for the differences in the outcome of these two trials, including the types of algorithms used, ethnic heterogeneity in COAG, and the comparator algorithm used—these have been extensively discussed in a recent review [55]. The importance of genotype in determining the risk of bleeding has been shown more recently in an analysis of the warfarin arm of the ENGAGE AF-TIMI 48 trial [57].

This review does not examine in depth established modes of pharmacogenetic variability via known associations, since a significant volume of literature already exists

(see Table 2). Based on this, the action column of the table lists the suggested action in individuals who are found to show the variation identified, where such advice has been issued. It aims instead to examine what progress has been made in recent years, and what might be hindering progress in this area, particularly from an application perspective.

## 5 Challenges for Clinical Implementation

As Table 2 demonstrates, robust genetic tests are available for a growing number of ADRs, though clearly much work is to be done in identifying genetic associations for many other ADRs. Even fewer have been implemented into clinical practice: two of the most prominent examples are abacavir and *HLA-B\*57:01* and carbamazepine and *HLA-B\*15:02*, which have demonstrated clinical utility [58, 59] and cost effectiveness of pre-prescription testing [60, 61]. Genetic variants in pharmacokinetic genes have fared even worse in terms of clinical implementation, although many associations that are convincing in terms of both biological plausibility and replicability have been described. Specific examples include *TMPT* testing for prevention of bone-marrow suppression from azathioprine/mercaptopurine therapy [19, 62], *CYP2C19* for clopidogrel/prasugrel anti-platelet treatment stratification [63], and *UGT1A1\*28* for prevention of irinotecan-induced neutropenia [64]. The lack of translation of pharmacogenomic associations into clinical practice thus represents a significant challenge for which there are many reasons [16, 65].

Given the rarity of many ADRs and the need for large sample sizes for discovery and independent cohorts for replication, it is often not possible for individual research groups to recruit the relevant number of cases and controls. Collaboration is therefore crucial, and this is beginning to happen through the formation of international consortia such as iSAEC [66], DILIGEN [67], EUDRAGENE [68] and RegiSCAR [69]. Findings such as the association between *HLA-B\*57:01* and flucloxacillin hepatotoxicity (an ADR with an incidence of 8.5/100,000 users) [67], demonstrate the power and potential of ‘combining forces’. No doubt, further robust ADR pharmacogenomic associations will be yielded using this approach in the future.

Some of the lack of reproducibility of genetic associations between independent research groups can be related to inconsistencies in the ADR phenotype definition. Initiatives have been established with the aim of standardizing phenotypes of key ADRs for application to pharmacogenetic studies with the aim of enhancing reproducibility of findings. Standardized phenotypes have been proposed for a range of ADRs, including drug-induced liver injury [70], skin injury [71], torsade de pointes [72], statin-induced

**Table 2** Some examples of known genetic associations with adverse drug reactions<sup>a</sup>

Drug	Reaction	Associated genetic variation	Action	References
Abacavir	Hepatotoxicity, cutaneous ADRs	<i>HLA-B*57:01</i>	Avoid	[125]
Allopurinol	Cutaneous ADRs	<i>HLA-B*58:01</i>	Avoid	[126–128]
Aminopenicillin	Delayed hypersensitivity reaction	<i>HLA-A2, HLA-DRW52</i>		[129]
Aspirin	Urticaria	<i>HLA-DRB1*13:02-DQB1*06:09</i>		[130]
Azathioprine	Bone marrow suppression	<i>TPMT*2/*3A/*3C/*4</i>	Dose adjustment	[62]
Capecitabine	Multi-system severe effects	DPD deficiency	Avoid	[131]
Carbamazepine	SJS/TEN, cutaneous and severe cutaneous ADRs	<i>HLA-B*15:02, HLA-A*31:01</i>	Avoid	[132, 133]
Celecoxib	Cardiovascular and GI events	<i>CYP2C9</i> -poor metabolizer	Dose reduction (50 %)	[134]
Chloroquine	Hemolysis	G6PD deficiency	Avoid	[135]
Co-amoxiclav	Hepatotoxicity	<i>HLA-A*02:01, DRB1*15:01-DQB1*06:02</i>		[136, 137]
Codeine	Opiate toxicity	<i>CYP2D6</i> -ultra rapid metabolizers ( <i>CYP2D6*1xN</i> and <i>CYP2D6*2xN</i> )	Avoid	[138, 139]
Clopidogrel	Bleeding	<i>CYP2C19*17</i>		[25]
Clozapine	Agranulocytosis	<i>HLA-DRB5*02:01</i>		[140]
Dapsone	Hemolysis	G6PD deficiency	Avoid	[141]
Doxepin	Arrhythmia; myelosuppression	<i>CYP2D6</i> -poor metabolizer	Dose reduction (60 %)	[142, 143]
Flucloxacillin	Hepatotoxicity	<i>HLA-B*57:01</i>	Avoid	[67]
5-Fluorouracil	Multi-system severe effects	DPD deficiency	Avoid	[144]
Flurbiprofen	Cardiovascular and GI events	<i>CYP2C9</i> -poor metabolizer	Dose reduction (50 %)	[145]
Irinotecan	Neutropenia	<i>UGT1A1*28</i>	Dose adjustment	[64]
Methazolamide	SJS, TEN	<i>HLA-B*59:01</i>		[146]
Mercaptopurine	Bone marrow suppression	<i>TPMT*2/*3A/*3C/*4</i>	Dose adjustment	[147]
Nevirapine	Hepatotoxicity, cutaneous ADRs	<i>HLA-Cw8-B14, HLA-Cw8, HLA-B*35:05, HLA-DRB*01:01, HLA-C*04:01</i>		[48, 148–151]
Oxicams	SJS, TEN	<i>HLA-B*73:01</i>		[152]
Phenytoin	SJS, TEN	<i>HLA-B*15:02</i> carrier	Avoid	[153]
Rasburicase	Hemolysis	G6PD deficiency	Avoid	[154]
Simvastatin	Myopathy	<i>SLCO1B1-c.521T&gt;C</i>	Dose adjustment	[155]
Sulfamethoxazole	SJS, TEN	<i>HLA-B*38:02</i>		[152]
Warfarin	Differing efficacy, risk of bleeding	<i>CYP2C9*2/*3 + VKORC1</i>	Dose adjustment	[156, 157]

ADR adverse drug reaction, *CYP* cytochrome P450, *DPD* dihydropyrimidine dehydrogenase, *G6PD* glucose-6-phosphate dehydrogenase, *HLA* human leukocyte antigen, *SLCO* solute carrier organic anion transporter, *SJS* Stevens–Johnson syndrome, *TEN* toxic epidermal necrolysis, *TPMT* thiopurine s-methyltransferase, *UGT* UDP-glucuronosyltransferase, *VKORC1* vitamin K epoxide reductase complex 1

<sup>a</sup> This is not intended as an exhaustive list of genetic–ADR associations

myopathy [73], and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker-induced angioedema [74]. It is hoped that adoption of these phenotypes by the wider pharmacogenetics field may lead to more reproducible findings and provide the greater weight of evidence required for clinical translation of ADR genetic associations.

A list of pharmacogenomic associations that have been identified and validated is regularly updated by the US FDA with label warnings to help prescribers [75]. Unfortunately, current prescribers have little awareness of this guidance and therefore there is little evidence that prescribing practice has yet changed [76, 77]. Furthermore, the pharmacogenetics information contained within drug labels can only

be of limited scope. For example, the drug label for codeine suggests that it should be avoided in *CYP2D6* ultra-rapid metabolizers due to the risk of morphine toxicity, and expert consensus supports this [78]. However, what is not clear in the drug label is exactly how the ‘ultra-rapid’ metabolizer phenotype should be derived from genotype data. Many laboratory tests exist that can determine this, but currently no standardized set of genetic markers is used. As such, there is a need to develop guidance that sits alongside the label that advises clinicians on the tests that can be undertaken, their interpretation, and any action that needs to be carried out [79]. This is now being realized through the publication of guidelines. For example, the Clinical Pharmacogenetics Implementation Consortium has published a significant number of guidelines for genotype-derived drug administration that are aimed at reducing toxicity. These have included *CYP2D6* and codeine toxicity [78], *TPMT* and azathioprine-induced bone marrow toxicity [80], and *SLCO1B1* and simvastatin-induced myopathy [81]. Similarly, the Royal Dutch Association for the Advancement of Pharmacy has set up a pharmacogenomics working group that has produced similar guidelines [82]. This should of course also be accompanied by further education and training for prescribers and healthcare managers who make budgetary decisions [83]. We know there is a lot of wastage of medicines in real-world clinical practice, and there is a need for further research to determine in a holistic manner whether better drug choice and drug doses through the use of pharmacogenomics would be cost effective. Indeed, a recent study suggested that one-time pharmacogenetic testing for preventing ADRs may be cost effective over a patient’s lifetime [84].

## 6 Pre-Emptive Genetic Testing

A concept currently gaining momentum is that of pre-emptively genotyping patients for key pharmacogenetic polymorphisms and providing this information within e-health records to prescribing physicians (across multiple medical specialties). A warning can then be flagged up to the prescriber, indicating that the genotype of the patient may have implications for the efficacy or toxicity of the drug they are prescribing. However, this concept relies on the provision of a strong, easily interpretable informatics component able to provide specific decision tools for drug/dose adjustment based on genotype. At present, within most healthcare settings, where patients are not routinely genotyped, it is difficult to apply any guidance, however benevolently intended. A number of feasibility studies for implementing pre-emptive testing are currently ongoing [80].

Despite the apparent promise of pre-emptive testing in averting ADRs, the testing is not without its critics. Hard

data on the clinical benefits of testing pre-emptively to justify the cost are lacking, and data on the comparative effectiveness of testing for genotypes is needed for those making financial decisions to justify funding such testing [85, 86]. In the EU, the clinical effectiveness of pre-emptive genetic testing will be tested over the coming years through the Ubiquitous Pharmacogenomics (U-PGx) Consortium (<http://upgx.eu/>).

## 7 Developing Areas

### 7.1 Point of Care (POC) Testing

One of the hurdles of testing for genotypes has been the cost and the timelines required to obtain results. Conventional laboratory genetic testing can take time and often this is a precious commodity when drug administration is required. Point-of-care (POC) testing, in principle removes the time issue and could potentially facilitate a much higher uptake of pre-emptive testing before prescribing. To date, implementation of POC testing for pharmacogenetics has largely been used for the optimization of the dose of the cardiovascular drugs warfarin and clopidogrel. Two recent trials, EU-PACT for warfarin [17] and RAPID-GENE for clopidogrel [87, 88], have used tests that produce a result in less than 120 minutes. Neither were strictly POC, as laboratories were used to analyze the samples, but both demonstrated the benefit of utilizing rapid portable genetic-testing devices prior to prescribing a drug. A number of FDA-approved kits are already available for POC testing for *CYP2C9*, *VKORC1*, and *CYP2C19*, including those used in the trials [88]. The future application of microfluidic technology [89] is likely to improve the portability of testing kits, and ease of use should improve rapidly, making true POC testing a real possibility. However, there are still some definite barriers to immediate expansion into ADR pharmacogenetics. Within the USA, clinics wishing to use POC testing will either require a CLIA (Clinical Laboratory Improvement Amendments) laboratory in which to do the testing or a waiver to test outside of this setting. Even with this waiver, FDA approval of the testing kit used is needed. In addition, current POC technologies are unable to type for HLA alleles, implicated in many ADRs, due to their very polymorphic loci, so some improvement is required in the basic technology before POC testing for polymorphisms in HLA is possible [88].

### 7.2 Companion Diagnostics

Drug-companion diagnostic combinations have traditionally been the domain of the field of oncology, with excellent examples such as trastuzumab in breast cancer



[90] and imatinib in gastrointestinal stromal tumors [91] demonstrating the increased efficacy of therapies in patients stratified by tumor molecular biology. Indeed, oncology drugs still comprise >40 % of all marketed drug–diagnostic combination products [92]. However, some notable non-cancer drug diagnostic combinations are in development for the optimization of treatment with anti-platelet drugs (clopidogrel or ticagrelor) for coronary artery disease/acute coronary syndrome [87]. There are currently no examples of stratifying companion diagnostics for the purpose of pre-emptive safety screening. However, it is conceivable that future drugs may be accompanied by such a test kit in order to moderate a drug safety profile.

## 8 Conclusions

Genetic factors predispose to ADRs to a variable extent. Many convincing and biologically plausible genetic associations with ADRs have been described, but very few have been implemented. There are many reasons for this, some of which have been covered in this review. Certainly, implementation of genetic testing will be helped by the continuous advances in genotyping technology, which is becoming increasingly accessible, faster, cheaper, and easier to use. However, this needs to be accompanied by generation of a relevant and robust evidence base that shows that genotyping impacts clinically on patient outcomes. This is needed irrespective of whether the genotyping is reactive or pre-emptive, as this is the only way that the clinical community will embrace this approach. Another major challenge is that the knowledge of the reach and potential of personalized medicine is still limited in all healthcare settings. Thus, educating those who deliver healthcare in the relevance of pharmacogenomics and the benefits for their patients is an important step. This should be accompanied by careful consideration of the cost effectiveness of testing, and acceptance by payers of the relevance of genetic testing. It is interesting to note that the increasing use of genetic testing prior to the prescription of clopidogrel in the USA has resulted in the test being funded via Medicare [93]. Without these developments, introduction of regular testing with rapidly available results will be challenging [85].

### Compliance with Ethical Standards

**Funding** The authors thank the MRC Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine for support. Munir Pirmohamed is a National Institute of Health Research Senior Investigator.

**Conflict of interest** Susannah Collins, Daniel Carr and Munir Pirmohamed have no conflicts of interest that are directly relevant to the content of this review.

## References

1. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. *Nature*. 1953;171(4356):737–8.
2. Vogel F. Moderne probleme der Humangenetik. *Ergeb Inn Med Kinderheilkd*. 1959;12:52–125.
3. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. *Science*. 2001;291(5507):1304–51.
4. Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. *Clin Pharmacol Ther*. 2014;96(6):655–7.
5. Poste G. Bring on the biomarkers. *Nature*. 2011;469(7329):156–7.
6. Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. *Expert Rev Clin Pharmacol*. 2008;1(5):695–705.
7. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. *BMJ*. 2004;329(7456):15–9.
8. Wei CY, Lee MT, Chen YT. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. *Hum Mol Genet*. 2012;21(R1):R58–65.
9. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. *Textbook of adverse drug reactions*. Oxford: Oxford University Press; 1977. p. 44.
10. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. *BMJ*. 2003;327(7425):1222–5.
11. International HapMap C. The International HapMap Project. *Nature*. 2003;426(6968):789–96.
12. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res*. 2014;42(Database issue):D1001–6.
13. Carr DF, Alfirevic A, Pirmohamed M. Pharmacogenomics: current state-of-the-art. *Genes (Basel)*. 2014;5(2):430–43.
14. A map of human genome variation from population-scale sequencing. *Nature*. 2010;467(7319):1061–73.
15. Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. *Pharmacogenomics*. 2014;15(14):1771–90.
16. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. *Annu Rev Genomics Hum Genet*. 2014;15:349–70.
17. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med*. 2013;369(24):2294–303.
18. Ring HZ, Kroetz DL. Candidate gene approach for pharmacogenetic studies. *Pharmacogenomics*. 2002;3(1):47–56.
19. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. *Clin Pharmacol Ther*. 1989;46(2):149–54.
20. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J*. 2005;5(1):6–13.
21. Llerena A, Naranjo ME, Rodrigues-Soares F, Penas LEM, Farinas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. *Expert Opin Drug Metabol Toxicol*. 2014;10(11):1569–83.

22. Smith RL. Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance. *Eur J Clin Pharmacol*. 1985;28(Suppl):77–84.
23. Stranger BE, Stahl EA, Raj T. Progress and promise of genome-wide association studies for human complex trait genetics. *Genetics*. 2011;187(2):367–83.
24. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, et al. Genome-wide association studies in pharmacogenomics: successes and lessons. *Pharmacogenet Genomics*. 2013;23(8):383–94.
25. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA*. 2009;302(8):849–57.
26. Spencer CC, Su Z, Donnelly P, Marchini J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. *PLoS Genet*. 2009;5(5):e1000477.
27. Levin AM, Adrianto I, Datta I, Iannuzzi MC, Trudeau S, McKeigue P, et al. Performance of HLA allele prediction methods in African Americans for class II genes HLA-DRB1, -DQB1, and -DPB1. *BMC Genet*. 2014;15:72.
28. Zheng X, Shen J, Cox C, Wakefield JC, Ehm MG, Nelson MR, et al. HIBAG–HLA genotype imputation with attribute bagging. *Pharmacogenomics J*. 2014;14(2):192–200.
29. Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, Nelson MR, et al. Multi-population classical HLA type imputation. *PLoS Comput Biol*. 2013;9(2):e1002877.
30. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy—a genome-wide study. *N Engl J Med*. 2008;359(8):789–99.
31. Jiao S, Hsu L, Hutter CM, Peters U. The use of imputed values in the meta-analysis of genome-wide association studies. *Genet Epidemiol*. 2011;35(7):597–605.
32. Marchini J, Howie B. Genotype imputation for genome-wide association studies. *Nat Rev Genetics*. 2010;11(7):499–511.
33. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet*. 2012;44(8):955–9.
34. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. *Nat Methods*. 2012;9(2):179–81.
35. Howey R, Cordell HJ. Imputation without doing imputation: a new method for the detection of non-genotyped causal variants. *Genet Epidemiol*. 2014;38(3):173–90.
36. Hoggart CJ, Whittaker JC, De Iorio M, Balding DJ. Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies. *PLoS Genet*. 2008;4(7):e1000130.
37. Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study designs and statistical tests. *Am J Hum Genet*. 2014;95(1):5–23.
38. Potamias G, Lakiotaki K, Katsila T, Lee MT, Topouzis S, Cooper DN, et al. Deciphering next-generation pharmacogenomics: an information technology perspective. *Open Biol*. 2014;4(7):pii: 140071.
39. Mizzi C, Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR, et al. Personalized pharmacogenomics profiling using whole-genome sequencing. *Pharmacogenomics*. 2014;15(9):1223–34.
40. Campbell H, Rudan I. Interpretation of genetic association studies in complex disease. *Pharmacogenomics J*. 2002;2(6):349–60.
41. Siu H, Zhu Y, Jin L, Xiong M. Implication of next-generation sequencing on association studies. *BMC Genomics*. 2011;12:322.
42. Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. *Pharmacogenomics*. 2012;13(5):579–94.
43. Ichihara A, Wang Z, Jinnin M, Izuno Y, Shimozono N, Yamane K, et al. Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions. *J Allergy Clin Immunol*. 2014;133(4):1065–74.
44. Sato S, Ichihara A, Jinnin M, Izuno Y, Fukushima S, Ihn H. Serum miR-124 up-regulation as a disease marker of toxic epidermal necrolysis. *Eur J Dermatol*. 2015.
45. Dear JW, Antoine DJ, Starkey-Lewis P, Goldring CE, Park BK. Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis. *Br J Clin Pharmacol*. 2014;77(5):904–5.
46. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. *Hepatology*. 2011;54(5):1767–76.
47. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. *Nature*. 2011;472(7344):495–8.
48. Carr DF, Chaponda M, Jorgensen AL, Castro EC, van Oosterhout JJ, Khoo SH, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. *Clin Infect Dis*. 2013;56(9):1330–9.
49. Ciccacci C, Rufini S, Politi C, Novelli G, Forte V, Borgiani P. Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes. *Thromb Res*. 2015;136(2):367–70.
50. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. *Lancet*. 2006;368(9536):704.
51. Pirmohamed M, Ostrov DA, Park BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. *J Allergy Clin Immunol*. 2015;136(2):236–44.
52. Sousa-Pinto B, Pinto-Ramos J, Correia C, Goncalves-Costa G, Gomes L, Gil-Mata S, et al. Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B\*57:01. *J Allergy Clin Immunol*. 2015;136(4):1092–1094.e3.
53. Guzey C, Spigset O. Genotyping of drug targets: a method to predict adverse drug reactions? *Drug Saf*. 2002;25(8):553–60.
54. Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. *Nat Genet*. 2015;47(3):263–6.
55. Pirmohamed M, Kamali F, Daly AK, Wadelius M. Oral anticoagulation: a critique of recent advances and controversies. *Trends Pharmacol Sci*. 2015;36(3):153–63.
56. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med*. 2013;369(24):2283–93.
57. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet*. 2015;385(9984):2280–7.
58. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B\*1502 screening in Taiwan. *N Engl J Med*. 2011;364(12):1126–33.
59. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B\*5701 screening for hypersensitivity to abacavir. *N Engl J Med*. 2008;358(6):568–79.
60. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B\*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. *Neurology*. 2012;79(12):1259–67.

61. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B\*5701 genotyping in preventing abacavir hypersensitivity. *Pharmacogenetics*. 2004;14(6):335–42.
62. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther*. 2011;89(3):387–91.
63. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. *N Engl J Med*. 2010;363(18):1704–14.
64. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al. UGT1A1\*28 polymorphism as a determinant of irinotecan disposition and toxicity. *Pharmacogenomics J*. 2002;2(1):43–7.
65. Pirmohamed M. Pharmacogenetics: past, present and future. *Drug Discov Today*. 2011;16(19–20):852–61.
66. Holden AL. The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse events. *Drug Discov Today Technol*. 2007;4(2):75–87.
67. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B\*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet*. 2009;41(7):816–9.
68. Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. *Pharmacogenomics*. 2006;7(4):633–8.
69. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. *Br J Dermatol*. 2013;169(5):1071–80.
70. Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. *Clin Pharmacol Ther*. 2011;89(6):784–5.
71. Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, et al. Phenotype standardization for immune-mediated drug-induced skin injury. *Clin Pharmacol Ther*. 2011;89(6):896–901.
72. Behr ER, January C, Schulze-Bahr E, Grace AA, Kaab S, Fiszman M, et al. The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. *Eur Heart J*. 2013;34(26):1958–63.
73. Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, et al. Phenotype standardization for statin-induced myotoxicity. *Clin Pharmacol Ther*. 2014;96(4):470–6.
74. Wadelius M, Marshall SE, Islander G, Nordang L, Karawajczyk M, Yue QY, et al. Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system. *Clin Pharmacol Ther*. 2014;96(4):477–81.
75. US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. 2013 [cited 2013 6th November]. Available from: <http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm>.
76. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. *Pharmacogenet Genom*. 2006;16(12):847–54.
77. Chen DT, Wynia MK, Moloney RM, Alexander GC. US physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. *Pharmacoepidemiol Drug Saf*. 2009;18(11):1094–100.
78. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin Pharmacol Ther*. 2012;91(2):321–6.
79. Overby CL, Devine EB, Abernethy N, McCune JS, Tarczy-Hornoch P. Making pharmacogenomic-based prescribing alerts more effective: a scenario-based pilot study with physicians. *J Biomed Inform*. 2015;55:249–59.
80. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Ann Rev Pharmacol Toxicol*. 2015;55:89–106.
81. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. *Clin Pharmacol Ther*. 2012;92(1):112–7.
82. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte—an update of guidelines. *Clin Pharmacol Ther*. 2011;89(5):662–73.
83. Stanek EJ, Sanders CL, Taber KAJ, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. *Clin Pharmacol Ther*. 2012;91(3):450–8.
84. Alagoz O, Durham D, Kasirajan K. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. *Pharmacogenomics J*. 2015. doi:10.1038/tpj.2015.39
85. Janssens AC, Deverka PA. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. *Clin Pharmacol Ther*. 2014;96(6):652–4.
86. Pirmohamed M. Pharmacogenetics of idiosyncratic adverse drug reactions. *Handb Exp Pharmacol*. 2010;196:477–91.
87. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. *Lancet*. 2012;379(9827):1705–11.
88. Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA. Implementation and utilization of genetic testing in personalized medicine. *Pharmacogenomics Pers Med*. 2014;7:227–40.
89. Hsieh K, Ferguson BS, Eisenstein M, Plaxco KW, Soh HT. Integrated electrochemical microsystems for genetic detection of pathogens at the point of care. *Accounts Chem Res*. 2015;48(4):911–20.
90. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. *Oncologist*. 2009;14(4):320–68.
91. Debiec-Rychter M, Sciort R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer*. 2006;42(8):1093–103.
92. Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. *Pharmacogenomics Pers Med*. 2015;8:99–110.
93. Dolgin E. Preemptive genotyping trialed to prevent adverse drug reactions. *Nat Med*. 2011;17(11):1323.
94. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. *Clin Ther*. 2001;23(10):1603–14.
95. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N, et al. Adverse events associated with

- nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS*. 2013;27(9):1403–12.
96. Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. *Expert Opin Drug Saf*. 2010;9(1):15–21.
  97. Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. *Expert Opin Drug Saf*. 2012;11(5):767–78.
  98. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. *Expert Opin Drug Saf*. 2004;3(6):655–65.
  99. Ramasamy SN, Korb-Wells CS, Kannagara DR, Smith MW, Wang N, Roberts DM, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. *Drug Saf Int J Med Toxicol Drug Exp*. 2013;36(10):953–80.
  100. Riahi RR, Cohen PR. Voriconazole-associated phototoxicity. *Dermatol Online J*. 2011;17(2):15.
  101. Andrews E, Daly AK. Flucloxacillin-induced liver injury. *Toxicology*. 2008;254(3):158–63.
  102. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. *J Gastroenterol Hepatol*. 2008;23(2):192–202.
  103. Davila-Fajardo CL, Swen JJ, Cabeza Barrera J, Guchelaar HJ. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. *Pharmacogenomics*. 2013;14(1):63–73.
  104. Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. *Nat Genet*. 2014;46(10):1131–4.
  105. Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. *Drugs*. 2015;75(12):1335–48.
  106. Lanás A. A review of the gastrointestinal safety data—a gastroenterologist's perspective. *Rheumatology*. 2010;49(Suppl 2):ii3–10.
  107. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. *Curr Drug Saf*. 2007;2(2):147–54.
  108. John R, Herzenberg AM. Renal toxicity of therapeutic drugs. *J Clin Pathol*. 2009;62(6):505–15.
  109. Gagnon RF, Alli AI, Watters AK, Tsoukas CM. Indinavir crystalluria. *Kidney Int*. 2006;70(12):2047.
  110. Miguel A, Henriques F, Azevedo LF, Pereira AC. Ophthalmic adverse drug reactions to systemic drugs: a systematic review. *Pharmacoepidemiol Drug Saf*. 2014;23(3):221–33.
  111. Gokulgandhi MR, Vadlapudi AD, Mitra AK. Ocular toxicity from systemically administered xenobiotics. *Expert Opin Drug Metabol Toxicol*. 2012;8(10):1277–91.
  112. Bitter I, Filipovits D, Czobor P. Adverse reactions to duloxetine in depression. *Expert Opin Drug Saf*. 2011;10(6):839–50.
  113. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. *Aliment Pharmacol Ther*. 2010;31(1):11–9.
  114. Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. *Expert Opin Drug Saf*. 2013;12(6):841–6.
  115. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. *Am Heart J*. 2014;168(1):6–15.
  116. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. *Pharmacotherapy*. 2004;24(12):1784–92.
  117. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. *J Clin Invest*. 2005;115(8):2025–32.
  118. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). *BMJ*. 1990;300(6736):1375–6.
  119. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. *Med Res Rev*. 2014;34(1):106–35.
  120. Inokuma S. Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. *Expert Opin Drug Saf*. 2011;10(4):603–11.
  121. Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. *Expert Opin Drug Saf*. 2003;2(6):587–96.
  122. Rasmusson L, Abtahi J. Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. *Int J Dent*. 2014;2014:471035.
  123. Ross CJ, Katzov-Eckert H, Dube MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. *Nat Genet*. 2009;41(12):1345–9.
  124. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. *Hearing Res*. 2011;281(1–2):28–37.
  125. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet*. 2002;359(9312):1121–2.
  126. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B\*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proc Natl Acad Sci USA*. 2005;102(11):4134–9.
  127. Tassaneeyakul W, Jantararungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B\*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. *Pharmacogenet Genomics*. 2009;19(9):704–9.
  128. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. *Pharmacogenomics*. 2008;9(11):1617–22.
  129. Romano A, De Santis A, Romito A, Di Fonso M, Venuti A, Gasbarrini GB, et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. *Ann Allergy Asthma Immunol*. 1998;80(5):433–7.
  130. Kim SH, Choi JH, Lee KW, Kim SH, Shin ES, Oh HB, et al. The human leucocyte antigen-DRB1\*1302-DQB1\*0609-DPB1\*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. *Clin Exp Allergy*. 2005;35(3):339–44.
  131. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. *Pharmacogenomics*. 2002;3(4):485–92.
  132. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B\*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. *Pharmacogenomics*. 2008;9(10):1543–6.
  133. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A\*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. *N Engl J Med*. 2011;364(12):1134–43.
  134. Prieto-Perez R, Ochoa D, Cabaleiro T, Roman M, Sanchez-Rojas SD, Talegon M, et al. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. *J Clin Pharmacol*. 2013;53(12):1261–7.
  135. Brewer GJ, Zarafone CJ. Haemolytic effect of various regimens of primaquine with chloroquine in American negroes with G6pd deficiency and lack of an effect of various antimalarial

- suppressive agents on erythrocyte metabolism. *B World Health Organ.* 1967;36(2):303.
136. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin–clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology.* 2011;141(1):338–47.
137. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RM, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. *Gut.* 2000;47(5):717–20.
138. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med.* 2004;351(27):2827–31.
139. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther.* 2014;95(4):376–82.
140. Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. Hla associations in clozapine-induced agranulocytosis. *Blood.* 1995;86(3):1177–83.
141. Grossman S, Budinsky R, Jollow D. Dapsone-induced hemolytic-anemia—role of glucose-6-phosphate-dehydrogenase in the hemolytic response of rat erythrocytes to *N*-hydroxydapsone. *J Pharmacol Exp Ther.* 1995;273(2):870–7.
142. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. *Pharmacogenetics.* 2002;12(7):571–80.
143. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. *Clin Pharmacol Ther.* 2013;93(5):402–8.
144. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase-deficiency—a potentially more common pharmacogenetic syndrome. *Cancer.* 1991;68(3):499–501.
145. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? *Drug Metab Dispos.* 2005;33(11):1567–75.
146. Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, et al. HLA-B\*5901 is strongly associated with methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis. *Pharmacogenomics.* 2010;11(6):879–84.
147. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. *JAMA.* 2005;293(12):1485–9.
148. Chantarangsu S, Mushirola T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. *Clin Infect Dis.* 2011;53(4):341–8.
149. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. *AIDS.* 2007;21(2):264–5.
150. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. *AIDS.* 2006;20(12):1621–6.
151. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1\*0101 and abrogated by low CD4 T-cell counts. *AIDS.* 2005;19(1):97–9.
152. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenet Genom.* 2008;18(2):99–107.
153. Lochareernkul C, Loplumert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B\*1502 allele in Thai population. *Epilepsia.* 2008;49(12):2087–91.
154. Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. *Ann Pharmacother.* 2005;39(11):1932–5.
155. Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. *PLoS Curr.* 2013;5. doi:10.1371/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203.
156. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anti-coagulant effect of warfarin. *Blood.* 2005;105(2):645–9.
157. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. *Blood.* 2005;106(7):2329–33.